{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=25&state=Massachusetts",
    "query": {
      "state": "Massachusetts",
      "city": "Boston",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 21516,
    "total_pages": 2152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=26&state=Massachusetts&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=24&state=Massachusetts&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T00:41:54.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02570490",
      "title": "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Bacterial Skin and Skin Structure Infections"
      ],
      "interventions": [
        {
          "name": "sodium fusidate",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrevus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2015-11",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2019-04-19",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 60,
      "location_summary": "Anaheim, California • Bakersfield, California • Buena Park, California + 46 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02570490"
    },
    {
      "nct_id": "NCT05186818",
      "title": "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstructive Hypertrophic Cardiomyopathy (oHCM)"
      ],
      "interventions": [
        {
          "name": "Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match aficamten",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cytokinetics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 282,
      "start_date": "2022-02-01",
      "completion_date": "2023-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 48,
      "location_summary": "Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05186818"
    },
    {
      "nct_id": "NCT01068418",
      "title": "Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Vitamin D Deficiency",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Vitamin D (cholecalciferol)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 26,
      "start_date": "2010-02",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068418"
    },
    {
      "nct_id": "NCT02512718",
      "title": "Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Omegaven",
          "type": "DRUG"
        },
        {
          "name": "Soybean oil lipid emulsion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexandra N. Carey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-06",
      "completion_date": "2023-05-18",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02512718"
    },
    {
      "nct_id": "NCT00001118",
      "title": "Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Enfuvirtide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 24,
      "location_summary": "La Jolla, California • Long Beach, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001118"
    },
    {
      "nct_id": "NCT05195918",
      "title": "Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "EGCG 300 mg + Nintedanib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "EGCG 300 mg + Pirfenidone",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 2 capsules + Nintedanib or Pirfenidone",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "EGCG 600 mg + Nintedanib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "EGCG 600 mg + Pirfenidone",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 4 capsules + Nintedanib or Pirfenidone",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Hal Chapman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-08-24",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05195918"
    },
    {
      "nct_id": "NCT04955990",
      "title": "A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "PAH Therapies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2021-10-14",
      "completion_date": "2022-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 15,
      "location_summary": "Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955990"
    },
    {
      "nct_id": "NCT04778397",
      "title": "Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Magrolimab",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Steroidal Eye Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-07-01",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-05",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04778397"
    },
    {
      "nct_id": "NCT00023348",
      "title": "TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Rifabutin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "1999-07",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2005-09-13",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023348"
    },
    {
      "nct_id": "NCT03653143",
      "title": "JASPER Intervention in Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Down Syndrome, Trisomy 21"
      ],
      "interventions": [
        {
          "name": "JASPER",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "48 Months",
        "sex": "ALL",
        "summary": "24 Months to 48 Months"
      },
      "enrollment_count": 12,
      "start_date": "2018-12-01",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2022-01-18",
      "last_synced_at": "2026-11-15T00:41:54.941Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03653143"
    }
  ]
}